Literature DB >> 7750992

Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens.

C Henne1, F Schwenk, N Koch, P Möller.   

Abstract

Whether or not intracellular transport and surface expression of the invariant chain (Ii; CD74) occurs independent of the presence of major histocompatibility complex (MHC) class II molecules was examined by comparing the class II-negative mutant lymphoblastoid cell line 174 x CEM.T2 (T2) and its class II-positive parental cell line 174 x CEM.T1 (T1). We found a similar proportion of Ii being transported to the Golgi complex in T1 and T2, as monitored by the degree of sialic acid addition to glycan side chains of Ii. In agreement with this result, T1 and T2 expressed comparable amounts of Ii at the cell surface, as measured by flow cytometry. This indicates that, although not associated with class II molecules, a proportion of Ii is transported to the plasma membrane. Both in T1 and T2, surface Ii (sIi) was rapidly internalized with a half-life of 3-4 min, suggesting that some Ii enters the endocytic route via the cell surface after being internalized. Our data demonstrate transport of Ii on a route alternative to the endocytic pathway. This alternative route could also account for delivery of newly synthesized class II-Ii complexes to processing compartments in antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7750992      PMCID: PMC1415095     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

Review 1.  The biochemistry and cell biology of antigen processing and presentation.

Authors:  R N Germain; D H Margulies
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

2.  Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers.

Authors:  J R Newcomb; P Cresswell
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

3.  Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization.

Authors:  P A Roche; C L Teletski; E Stang; O Bakke; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

4.  Cell-surface expression of human histocompatibility leucocyte antigen (HLA) class II-associated invariant chain (CD74) does not always correlate with cell-surface expression of HLA class II molecules.

Authors:  K M Wilson; M O Labeta; G Pawelec; N Fernandez
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

5.  Membrane insertion and oligomeric assembly of HLA-DR histocompatibility antigens.

Authors:  S Kvist; K Wiman; L Claesson; P A Peterson; B Dobberstein
Journal:  Cell       Date:  1982-05       Impact factor: 41.582

6.  Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens.

Authors:  C E Machamer; P Cresswell
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

7.  Invariant chain retains MHC class II molecules in the endocytic pathway.

Authors:  G E Loss; A J Sant
Journal:  J Immunol       Date:  1993-04-15       Impact factor: 5.422

8.  Monoclonal anti-Ia murine alloantibodies crossreactive with the Ia-homologues of other mammalian species including humans.

Authors:  M Watanabe; T Suzuki; M Taniguchi; N Shinohara
Journal:  Transplantation       Date:  1983-12       Impact factor: 4.939

9.  Stable surface expression of invariant chain prevents peptide presentation by HLA-DR.

Authors:  P A Roche; C L Teletski; D R Karp; V Pinet; O Bakke; E O Long
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598

10.  The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail.

Authors:  J Pieters; O Bakke; B Dobberstein
Journal:  J Cell Sci       Date:  1993-11       Impact factor: 5.285

View more
  19 in total

1.  The expansion of human gammadelta T cells in response to Daudi cells requires the participation of CD4+ T cells.

Authors:  J D Fayen; M L Tykocinski
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

2.  Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.

Authors:  Salahaldin A Tahir; Jianjun Gao; Yuji Miura; Jorge Blando; Rebecca S S Tidwell; Hao Zhao; Sumit K Subudhi; Hussein Tawbi; Emily Keung; Jennifer Wargo; James P Allison; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

3.  A functional heteromeric MIF receptor formed by CD74 and CXCR4.

Authors:  Verena Schwartz; Hongqi Lue; Sandra Kraemer; Joanna Korbiel; Regina Krohn; Kim Ohl; Richard Bucala; Christian Weber; Jürgen Bernhagen
Journal:  FEBS Lett       Date:  2009-08-06       Impact factor: 4.124

4.  Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines.

Authors:  G L Ong; D M Goldenberg; H J Hansen; M J Mattes
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

5.  HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection.

Authors:  Chang Zhou; Lu Lu; Suiyi Tan; Shibo Jiang; Ying-Hua Chen
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

Review 6.  Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Joshua B Bilsborrow; Edward Doherty; Pathricia V Tilstam; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2019-08-20       Impact factor: 6.902

7.  Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors.

Authors:  Sofia Lourenco; Vitor H Teixeira; Tammy Kalber; Ricardo J Jose; R Andres Floto; Sam M Janes
Journal:  J Immunol       Date:  2015-02-23       Impact factor: 5.422

8.  A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform.

Authors:  Magdalena Pyrz; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

9.  Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass.

Authors:  Se Hwan Mun; Hee Yeon Won; Paula Hernandez; Hector Leonardo Aguila; Sun-Kyeong Lee
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

Review 10.  CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract.

Authors:  Ellen J Beswick; Victor E Reyes
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.